New Potential Site For Medications To Target Persistent Seizures In Epileptic Patients

Main Category: Epilepsy
Article Date: 19 Jan 2013 - 0:00 PST

Current ratings for:
New Potential Site For Medications To Target Persistent Seizures In Epileptic Patients

Patient / Public:not yet rated

Healthcare Prof:4 stars

4 (1 votes)


In a promising finding for epileptic patients suffering from persistent seizures known as status epilepticus, researchers reported that new medication could help halt these devastating seizures. To do so, it would have to work directly to antagonize NMDA receptors, the predominant molecular device for controlling synaptic activity and memory function in the brain.

"Despite the development of new medications to prevent seizures, status epilepticus remains a life-threatening condition that can cause extensive brain damage in the patients that survive these persistent seizures," said David E. Naylor, MD, PhD, a lead researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and corresponding author of the new study. "Our research holds promise for the development of new therapies to treat this devastating condition because we have found a potential new target for medical intervention that should bolster the current standard therapies to treat the acute seizures. It may also prevent the long-term adverse effects of persistent seizure activity on the brain."

The research, reported online in the Neurology of Disease journal, used animal models to assess cellular activity in the brain during persistent seizures. It found that the seizure activity seemed to force the NMDA receptors from the interior to the surface of nerve cells causing their activity to increase by approximately 38%.

"The increased presence of the NMDA receptors on the cell surface during these seizures may explain the successful use of NMDA antagonists - medication that inhibits the activity of the NMDA receptors in the brain - in the latter stages of a seizure, long after other medications have stopped working," said Dr. Naylor. "We concluded that medications that suppress the activity of the NMDA receptors, in conjunction with other medications, may be successful in stopping persistent seizures. Further research is, of course, needed."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our epilepsy section for the latest news on this subject.
In addition to Dr. Naylor, the researchers who participated in the study were Drs. Hantao Liu at the Veterans Administration Greater Los Angeles County Healthcare System's Department of Neurology and Jerome Niquet and Claude G. Wasterlain of the David Geffen School of Medicine at the University of California, Los Angeles Department of Neurology. The research was funded by LA BioMed and a Veterans Administration Career Development Award. The study may be viewed online at http://www.sciencedirect.com/science/article/pii/S0969996113000065

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Los Angeles Biomedical Research Institute at Harbo. "New Potential Site For Medications To Target Persistent Seizures In Epileptic Patients." Medical News Today. MediLexicon, Intl., 19 Jan. 2013. Web.
25 May. 2013. <http://www.medicalnewstoday.com/releases/255058.php>

APA
Los Angeles Biomedical Research Institute at Harbo. (2013, January 19). "New Potential Site For Medications To Target Persistent Seizures In Epileptic Patients." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/255058.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'New Potential Site For Medications To Target Persistent Seizures In Epileptic Patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Epilepsy

Most Popular Articles



Follow Our Epilepsy News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Epilepsy Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »